Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1997 1
1998 5
1999 5
2000 3
2001 1
2002 3
2003 1
2004 1
2005 2
2007 6
2008 12
2009 14
2010 17
2011 19
2012 15
2013 16
2014 6
2015 11
2016 5
2017 4
2018 9
2019 7
2020 3
2021 11
2022 4
2023 10
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Tostmann A, et al. Among authors: boeree mj. J Gastroenterol Hepatol. 2008 Feb;23(2):192-202. doi: 10.1111/j.1440-1746.2007.05207.x. Epub 2007 Nov 6. J Gastroenterol Hepatol. 2008. PMID: 17995946 Review.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: boeree mj. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Free PMC article. Review.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilb… See abstract for full author list ➔ Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Among authors: boeree mj. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Lancet. 2018. PMID: 30215381 Free PMC article. Review.
XDR tuberculosis.
van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D. van Ingen J, et al. Among authors: boeree mj. Lancet Infect Dis. 2011 Aug;11(8):585. doi: 10.1016/S1473-3099(11)70200-6. Lancet Infect Dis. 2011. PMID: 21798459 No abstract available.
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. van Ingen J, et al. Among authors: boeree mj. Clin Infect Dis. 2011 May;52(9):e194-9. doi: 10.1093/cid/cir184. Clin Infect Dis. 2011. PMID: 21467012 Review.
181 results